Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
131.60
-0.96 (-0.72%)
Apr 2, 2026, 4:00 PM EDT - Market closed
Neurocrine Biosciences Employees
Neurocrine Biosciences had 2,000 employees as of December 31, 2025. The number of employees increased by 200 or 11.11% compared to the previous year.
Employees
2,000
Change (1Y)
200
Growth (1Y)
11.11%
Revenue / Employee
$1,430,250
Profits / Employee
$239,300
Market Cap
13.21B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,000 | 200 | 11.11% |
| Dec 31, 2024 | 1,800 | 400 | 28.57% |
| Dec 31, 2023 | 1,400 | 200 | 16.67% |
| Dec 31, 2022 | 1,200 | 300 | 33.33% |
| Dec 31, 2021 | 900 | 55 | 6.51% |
| Dec 31, 2020 | 845 | 145 | 20.71% |
| Dec 31, 2019 | 700 | 115 | 19.66% |
| Dec 31, 2018 | 585 | 185 | 46.25% |
| Dec 31, 2017 | 400 | 204 | 104.08% |
| Dec 31, 2016 | 196 | 76 | 63.33% |
| Dec 31, 2015 | 120 | 26 | 27.66% |
| Dec 31, 2014 | 94 | 13 | 16.05% |
| Dec 31, 2013 | 81 | 3 | 3.85% |
| Dec 31, 2012 | 78 | 7 | 9.86% |
| Dec 31, 2011 | 71 | 5 | 7.58% |
| Dec 31, 2010 | 66 | 1 | 1.54% |
| Dec 31, 2009 | 65 | -60 | -48.00% |
| Dec 31, 2008 | 125 | -10 | -7.41% |
| Dec 31, 2007 | 135 | -132 | -49.44% |
| Dec 31, 2006 | 267 | -321 | -54.59% |
| Dec 31, 2005 | 588 | 203 | 52.73% |
| Dec 31, 2004 | 385 | 40 | 11.59% |
| Dec 31, 2003 | 345 | 69 | 25.00% |
| Dec 31, 2002 | 276 | 54 | 24.32% |
| Dec 31, 2001 | 222 | 34 | 18.09% |
| Dec 31, 2000 | 188 | 37 | 24.50% |
| Dec 31, 1999 | 151 | 2 | 1.34% |
| Dec 31, 1998 | 149 | 41 | 37.96% |
| Dec 31, 1997 | 108 | 5 | 4.85% |
| Dec 31, 1996 | 103 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Teva Pharmaceutical Industries | 33,950 |
| Viatris | 30,000 |
| Dr. Reddy's Laboratories | 27,811 |
| Haleon | 24,535 |
| Elanco Animal Health | 9,900 |
| Amneal Pharmaceuticals | 8,700 |
| Hims & Hers Health | 2,442 |
| Alkermes | 2,050 |
NBIX News
- 9 days ago - Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings - PRNewsWire
- 17 days ago - Neurocrine Biosciences, Inc. (NBIX) Presents at Stifel 2026 Virtual CNS Forum Transcript - Seeking Alpha
- 18 days ago - Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer - PRNewsWire
- 25 days ago - Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum - PRNewsWire
- 26 days ago - Neurocrine Biosciences, Inc. (NBIX) Presents at Leerink Global Healthcare Conference 2026 Transcript - Seeking Alpha
- 4 weeks ago - BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX) - PRNewsWire
- 4 weeks ago - Neurocrine Biosciences, Inc. (NBIX) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 5 weeks ago - Neurocrine Biosciences to Present at Upcoming Investor Conferences in March - PRNewsWire